Anavex Life Sciences Corporation [NASDAQ: AVXL] closed the trading session at $5.69 on 2025-11-13. The day’s price range saw the stock hit a low of $5.1, while the highest price level was $7.25.
The stocks have a year to date performance of -37.81 percent and weekly performance of -23.11 percent. The stock has been moved at -32.02 percent over the last six months. The stock has performed -36.99 percent around the most recent 30 days and changed -42.79 percent over the most recent 3-months.
If compared to the average trading volume of 1.24M shares, AVXL reached to a volume of 8619060 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Anavex Life Sciences Corporation [AVXL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AVXL shares is $44.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AVXL stock is a recommendation set at 1.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Anavex Life Sciences Corporation shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 06, 2022. While these analysts kept the previous recommendation, Berenberg raised their target price to Buy. The new note on the price target was released on June 23, 2022, representing the official price target for Anavex Life Sciences Corporation stock. Previously, the target price had yet another raise to $35, while BTIG Research analysts kept a Buy rating on AVXL stock. On December 16, 2020, analysts increased their price target for AVXL shares from 14 to 17.
The Price to Book ratio for the last quarter was 5.34, with the Price to Cash per share for the same quarter was set at 1.18.
AVXL stock trade performance evaluation
Anavex Life Sciences Corporation [AVXL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -23.11. With this latest performance, AVXL shares dropped by -36.99% in over the last four-week period, additionally sinking by -32.02% over the last 6 months – not to mention a drop of -47.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AVXL stock in for the last two-week period is set at 21.61, with the RSI for the last a single of trading hit 0.69, and the three-weeks RSI is set at 0.59 for Anavex Life Sciences Corporation [AVXL]. The present Moving Average for the last 50 days of trading for this stock 8.62, while it was recorded at 6.64 for the last single week of trading, and 9.10 for the last 200 days.
Anavex Life Sciences Corporation (AVXL) Capital Structure & Debt Analysis
According to recent financial data for Anavex Life Sciences Corporation. ( AVXL), the Return on Equity (ROE) stands at -43.63%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -39.47%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Anavex Life Sciences Corporation’s Return on Invested Capital (ROIC) is -52.96%, showcasing its effectiveness in deploying capital for earnings.
Anavex Life Sciences Corporation (AVXL) Efficiency & Liquidity Metrics
Based on Anavex Life Sciences Corporation’s (AVXL) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Anavex Life Sciences Corporation (AVXL) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Anavex Life Sciences Corporation. (AVXL) effectively leverages its workforce, generating an average of -$1146904.76 per employee. The company’s liquidity position is robust, with a Current Ratio of 8.93% and a Quick Ratio of 8.93%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Anavex Life Sciences Corporation [AVXL] stock
With the latest financial reports released by the company, Anavex Life Sciences Corporation posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.03. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AVXL.
Anavex Life Sciences Corporation [AVXL]: Institutional Ownership
There are presently around $38.71%, or 40.06%% of AVXL stock, in the hands of institutional investors. The top three institutional holders of AVXL stocks are: BLACKROCK INC. with ownership of 6.39 million shares, which is approximately 7.5607%. VANGUARD GROUP INC, holding 4.55 million shares of the stock with an approximate value of $$19.19 million in AVXL stocks shares; and VANGUARD GROUP INC, currently with $$15.78 million in AVXL stock with ownership which is approximately 4.4246%.
